

Resource Summary Report

Generated by [RRID](#) on Sep 4, 2026

22Rv1

RRID:CVCL_1045

Type: Cell Line

Proper Citation

RRID:CVCL_1045

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1045

Proper Citation: RRID:CVCL_1045

Description: Cell line 22Rv1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Prostate carcinoma

Defining Citation: [PMID:10462204](#), [PMID:12725112](#), [PMID:14518029](#), [PMID:14518030](#), [PMID:15486987](#), [PMID:19403664](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:21248069](#), [PMID:22460905](#), [PMID:23117885](#), [PMID:23671654](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:27271795](#), [PMID:27397505](#), [PMID:28145883](#), [PMID:28928128](#), [PMID:30629668](#), [PMID:30787054](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31006810](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:31978347](#), [PMID:35839778](#), [PMID:38892296](#)

Comments: Virology: Contains at least 10 integrated copies of xenotropic murine leukemia virus-related virus (XMRV) genome and produces a high titer of the virus (PubMed=19403664; PubMed=30629668)., Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: 22Rv1

Synonyms: 22RV1, 22Rv-1, 22rV1, CWR-22rv1, CWR22-Rv1, CWR22R-V1, CWR22-R1, CWR22Rv1, CWR22R

Cross References: BTO:BTO_0002999, CLO:CLO_0001199, CLO:CLO_0001200, EFO:EFO_0002095, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-2505, BCRC:60545, BioGRID_ORCS_Cell_line:821, BioSample:SAMN03471600, BioSample:SAMN03472052, BioSample:SAMN05292447, BioSample:SAMN07710012, BioSample:SAMN07710013, BioSample:SAMN07710014, BioSample:SAMN07710015, BioSample:SAMN07710016, BioSample:SAMN07710017, BioSample:SAMN07710018, BioSample:SAMN10988315, cancercellines:CVCL_1045, CCRID:3101HUMSCSP5022, CCRID:3101HUMTCHu100, CCRID:4201HUM-CCTCC00288, CCRID:5301HUM-KCB07031YJ, CCTCC:GDC0288, Cell_Model_Passport:SIDM00499, ChEMBL-Cells:ChEMBL3308004, ChEMBL-Targets:ChEMBL612657, CLS:305037, Cosmic:924100, Cosmic:1028699, Cosmic:1071480, Cosmic:1075276, Cosmic:1172629, Cosmic:1330911, Cosmic:1689707, Cosmic:1995323, Cosmic:2537791, Cosmic:2580126, Cosmic:2651766, Cosmic:2669170, Cosmic-CLP:924100, DepMap:ACH-000956, DSMZ:ACC-438, DSMZCellDive:ACC-438, ECACC:05092802, EGA:EGAS00001000978, ENCODE:ENCBS070BKF, ENCODE:ENCBS383WOY, ENCODE:ENCBS596KKM, ENCODE:ENCBS626QQL, ENCODE:ENCBS737IZN, ENCODE:ENCBS822DIG, GDSC:924100, GEO:GSM91926, GEO:GSM525793, GEO:GSM648815, GEO:GSM827396, GEO:GSM886837, GEO:GSM887900, GEO:GSM1374375, GEO:GSM1633317, GEO:GSM1633318, GEO:GSM1633319, GEO:GSM1669565, GEO:GSM3145592, GEO:GSM3145703, IARC_TP53:18887, IGRhCellID:22Rv1, KCB:KCB_200731YJ, LiGeA:CCELE_229, LINC_S_LDP:LCL-1145, Lonza:1442, PharmacDB:22RV1_12_2019, PRIDE:PXD030304, Progenetix:CVCL_1045, PubChem_Cell_line:CVCL_1045, Ubigen:YC-C012, Wikidata:Q54583380

ID: CVCL_1045

Hierarchy: cvcl_3967

Record Creation Time: 20220427T215041+0000

Record Last Update: 20260904T021049+0000

Ratings and Alerts

No rating or validation information has been found for 22Rv1.

No alerts have been found for 22Rv1.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 959 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#).

Kim M, et al. (2026) Bone Metastatic Progression of Prostate Cancer Is Regulated by TRIM28-LDHA-Mediated Metabolism. *Molecular cancer research : MCR*, 24(2), 93.

Nayak S, et al. (2026) Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degradar and Antagonist, for the Treatment of Advanced Prostate Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(1), 224.

Shi W, et al. (2026) Targeting FANCD2 to overcome enzalutamide resistance in prostate cancer. *Cancer & metabolism*, 14(1).

Kalla J, et al. (2026) Biobank of genetically defined murine prostate cancer tumoroids uncovers oncogenic pathways and drug vulnerabilities driven by PTEN-loss. *Cell reports methods*, 6(4), 101370.

Dong G, et al. (2026) Discovery of SKP2-Recruiting PROTACs for Target Protein Degradation. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(20), e15159.

Lindsey GL, et al. (2026) Structural and mechanistic analysis of covalent ligands targeting the RNA-binding protein NONO. *Cell chemical biology*, 33(2), 256.

Gordon N, et al. (2026) PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer. *Molecular oncology*, 20(6), 1626.

Cunningham ML, et al. (2026) PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration-resistant prostate cancer. *Molecular oncology*, 20(2), 369.

Singh KB, et al. (2026) Restoration of Immune Surveillance in Prostate Cancer Prevention by Sulforaphane in Hi-Myc Mice. *Molecular carcinogenesis*, 65(6), 677.

O'Loughlin TA, et al. (2026) mTORC1 activity suppresses ferroptosis through a SCARB1-dependent HDL-tocopherol uptake pathway. *Molecular cell*, 86(8), 1546.

Tian Y, et al. (2026) Fine mapping regulatory variants by characterizing native CpG methylation with nanopore long-read sequencing. *HGG advances*, 7(1), 100532.

Li H, et al. (2026) YEATS2 promotes DNA repair and induces anoikis resistance by enhancing chromatin accessibility to drive prostate cancer metastasis. *Oncogene*, 45(11), 971.

Rodrigues SD, et al. (2026) Suppression of de novo lipogenesis and dietary PUFA supplementation inhibit prostate cancer progression. *bioRxiv : the preprint server for biology*.

Liu C, et al. (2026) Androgen Receptor-Induced Lactoferrin Accelerates Prostate Tumorigenesis Through Modulating Ferroptosis. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(37), e20109.

Koo KM, et al. (2026) Rapid Decentralized Prostate Cancer Risk Stratification by Portable Liquid Biopsy Analysis within a Clinical Biosensor Validation Framework. *Advanced*

science (Weinheim, Baden-Wurttemberg, Germany), 13(13), e12126.

Wilson A, et al. (2026) Inhibiting stearyl-CoA desaturase suppresses bone metastatic prostate cancer by modulating cellular stress, mTOR signaling, and DNA damage response. FEBS letters, 600(7), 1043.

Huang J, et al. (2026) The FOSB-IGFBP5-IGF-1 axis: a novel regulatory pathway that suppresses prostate cancer growth. Cancer gene therapy.

Bidkar AP, et al. (2026) Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody-Drug Conjugates. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(8), 1540.

Susa T, et al. (2026) Androgen Signaling Represses Homeobox C9, an Inhibitor of Androgen Receptor, in Prostate Cancer Cells. International journal of molecular sciences, 27(4).

Sun R, et al. (2026) KDM5B-driven glucose metabolic reprogramming promotes enzalutamide resistance in prostate cancer via the lactate/hnRNPA1 lactylation/AR-V7 axis. Molecular cancer, 25(1).